Investors Alert: Pomerantz Law Firm Announces Class Action Lawsuit Against Replimune Group, Inc.

In a critical update for shareholders, Pomerantz Law Firm has announced the initiation of a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL). This announcement is a significant development for investors who have suffered losses related to their stakes in the company. The firm encourages affected shareholders to reach out for further information regarding their potential involvement in this lawsuit.

Background of the Class Action

The class action centers on allegations that Replimune, alongside certain officers and directors, may have engaged in securities fraud or other unlawful business practices. Shareholders who acquired Replimune's securities during the specified period are urged to act by October 5, 2026, to request the court to appoint them as Lead Plaintiffs.

Details of the FDA's Rejection

In April 2026, the FDA issued a Complete Response Letter (CRL) rejecting Replimune's Biologics License Application (BLA) for its therapy RP1 in combination with nivolumab. The FDA outlined multiple deficiencies in the studies submitted by Replimune, ultimately concluding that the evidence provided did not satisfy the rigorous requirements for obtaining regulatory approval. The outcomes of the investigational studies, RPL-001-16 and RP1-104, were deemed insufficient.

The agency noted that the study designs' concerns had been communicated clearly throughout Replimune's developmental program but were not adequately addressed. Consequently, this rejection led to a significant decline in Replimune's stock price.

Market Reaction

In response to the FDA's announcement, Replimune's shares plummeted by $1.15 or approximately 19.46%, closing at $4.76 per share on the date of the news. Following further negative commentary from the company regarding the FDA's preferences for clinical trials, the share price declined even further, dropping to $1.70 by April 13, 2026, marking a staggering 64.29% decrease.

Contact Details for Affected Investors

Danielle Peyton of Pomerantz LLP can be contacted via email at [email protected] or through the firm's toll-free number at 888.4-POMLAW, ext. 7980. It is advised that investors include their contact information and details regarding their share purchases when reaching out.

About Pomerantz LLP

Founded over 85 years ago by Abraham L. Pomerantz, the law firm is recognized for its hard-hitting advocacy in the realm of corporate and securities litigation, particularly class actions. Notably, it has a successful track record of recovering substantial damages for victims of securities fraud and corporate misconduct. As a dedicated legal entity located in major cities across the globe, Pomerantz remains committed to fighting for the rights of affected shareholders.

For those eligible to join the class action, more information can be found at Pomerantz Law. This serves as an essential opportunity for shareholders seeking justicia amid concerning circumstances surrounding their investment in Replimune Group, Inc.